Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
ConclusionsThe pharmacokinetics of rivipansel was well characterized by a two-compartment population pharmacokinetic model. Our results illustrate the important role of simulations in optimizing a potential drug dosing regimen for patients with sickle cell disease and progressive renal impairment.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Children | Chronic Kidney Disease | Drugs & Pharmacology | Epidemiology | Pediatrics | Sickle Cell Anemia | Study | Urology & Nephrology